JUN 10, 2015 02:00 PM PDT

Personalized medicine

2 38 1065

  • Laboratory Director, KEW Group Inc.
      Dr. Lyle is a physician-scientist with expertise in the histopathologic, cellular and molecular analysis of cancer. In addition to his seminal work characterizing the molecular and biologic properties of adult stem cells, he has made significant contributions in translational cancer research and the commercialization of new diagnostics. He has previously served Laboratory Director of Predictive Biosciences, Aushon Biosystems, Eutropics Inc., Ardais Corp. and three site labs of Harvard Vanguard Medical Associates. He is also a former Medical Director of Catalyst Oncology, Inc.

      Dr. Lyle holds an appointment as Associate Professor of Cancer Biology and Pathology, UMass Medical School and is the Co-Director of the UMass Cancer Center Tissue Bank. He has held NIH and private foundation grants to study adult stem cell biology, cancer stem cells and skin biology. He has received a multiple awards, grants and fellowships from The NIH, William Keck Foundation, The Ellison Foundation, Dermatology Foundation, Burroughs Wellcome Trust, and The March of Dimes. He is an active member and Fellow of the College of American Pathologists, with a number of media appearances as a former Spokesperson, and is member of The American Association for Cancer Research. He is an author on over 65 research publications, several book chapters and reviews.

      Dr. Lyle graduated with honors from the University of Chicago in the combined B.A. / M.S. program in Biochemistry and then attended The Pritzker School of Medicine/University of Chicago where he completed his M.D. and Ph.D. in Biochemistry and Molecular Biology. He served as a resident and surgical pathology fellow at the University of Pennsylvania Hospital, where he received the prestigious HT Enterline Fellowship Award, and then completed his clinical training as a fellow in the Harvard Dermatopathology Program, Boston, MA.

    Matching the mutational profile of a patient's tumor with appropriate targeted agents is a goal of personalized medicine in oncology. The number of FDA-approved targeted therapies, as well as those entering clinical trials, is continually increasing. In addition, clinical trials based on molecular profiling ("Bucket Trials") are becoming widely available in community oncology practices. Molecular profiling of tumor tissues allows for comprehensive sequencing of large panels of genes to detect mutations, copy number changes and translocations. Currently, greater than 50 FDA-approved drugs target specific genetic pathways that are altered in cancer, and there are hundreds of clinical trials that are studying the association of targeted therapies in the context of specific genetic alterations. The results are rapidly being incorporated into treatment guidelines issued by the National Cancer Center Network that recommend multiplex next-generation sequencing to identify patients who are most likely to respond to newly approved drugs. The KEW Group's CancerPlex is a DNA-based next-generation sequencing test of >400 known cancer genes that includes all genes associated with FDA-approved targeted drugs, as well as drugs in clinical development. The entire coding regions of all genes in the panel are sequenced. Thus, in addition to common genetic variants, Cancerplex detects novel or rare mutations that are missed by other testing modalities. Copy number changes and translocations of ALK, RET and ROS genes are also analyzed in one comprehensive assay. Genetic findings are reported in easy to understand, clinically relevant categories based on proprietary genetic variant database with a turnaround time of 7-10 days. Utilization of the CancerPlex panel can identify actionable findings in >90% of patients.

    Show Resources
    Loading Comments...